CND Life Sciences Raises $5.0M in Series Seed 2 Funding
- CND LifeScience, a Phoenix AZ-based medical diagnostics company, raised $5M in Series Seed 2 funding
- The bakers were not disclosed
- The company intends to use the funds to continue commercial scale-up, broaden market education on Syn-One, and advance many R&D activities
- CND LifeSciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions
- CND launched the Syn-One Test as a test to detect, visualize, and quantify misfolded alpha-synuclein located in cutaneous nerve fibers
- The test, which analyzes small skin biopsies collected conveniently from the patient in a physician’s office, aids in the diagnosis of a synucleinopathy
